Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Advanced Enzymes announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve 'Long Covid' Fatigue Symptoms

Posted On: 2021-09-13 07:16:22 (Time Zone: UTC)


Advanced Enzyme Technologies Limited (AETL) (NSE: ADVENZYMES; BSE: 540025) today announced that its systemic enzyme and probiotic supplements-ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve post-COVID fatigue symptoms.

It's a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID-19 disease. However, there are no specific treatments available globally to treat post-COVID fatigue complications.

With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID-19 induced fatigue, a randomized, multi-centric, double blind and placebo-controlled trial was conducted in 200 patients suffering from post-COVID fatigue symptoms.

The test arm (100 patients) received the oral supplements for 14-days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL.

The randomized clinical trial was conducted on 200 patients that did not have an active SARS-CoV-2 infection, as determined by a negative COVID-19 test, with a complaint of post-COVID fatigue. Patients were required to have a positive COVID-19 test at any time in the past. The trial was conducted across three centres in India-Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14-days, informed Dr Rathi.

According to the clinical research paper published by the Switzerland-based "Medicines" Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ-11) for 14-days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14-day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14-day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved post-COVID-19 fatigue symptoms and improved patients' functional status and quality of life, informed Dr. Rathi.

The Coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7-10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID.

Studies revealed that about 52 percent of patients among the studied population showed fatigue/myalgia post-COVID-19.

A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID-19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms.

"Enzymes and probiotics are a robust mechanism to revitalize stamina and vitality, which is proved during the recently concluded randomized clinical trials," said Mr. Vasant Rathi, Chairman, AETL.

"Recent trials suggest that nutraceuticals product supplement succours in recovery of COVID patients. However, the patient-oriented outcome of the supplement may vary in individuals. For some, they may find a difference within couple of days, but for others, it may take a week or ten days. To avail long-term benefit and better results of the supplement, it's advisable to take the immunity bundle doses consistently every day for couple of months. However, in case you miss the dosage, don't' worry as it has no side effects," said Mr. Rathi.

"We have served the Americans since over last 30 years. But during the pandemic, our key focus was to enhance immunity amongst Indians. Hence, we went online with our research-backed immunity bundle. I feel, doctors need to address the issue of post-COVID immunity soon as its affecting quality of life," said Mr. Mukund Kabra, Director, Advanced Enzyme Technologies Limited (AET).

To benefit common people our researched-backed chemical-free post-COVID immune support bundle - ImmunoSEB and Biome Ultra (ProbioSEB CSC3), our company has beefed up our omnichannel presence across India and globally. We tasted our runaway success in the US markets amidst the pandemic, hence decided to list our flagship immune support brands across online marketplaces in India to target a larger swath of pill-fatigued, healthy agers, immunity conscious millennials, and Gen Z, said Mr Kabra.

Meanwhile, the products are currently available globally on the leading e-commerce marketplace - Amazon. In a move to further shore up its direct-to-customer (D2C) omnichannel retailing business, AETL has unveil its online store - 'Advanced Enzymes e-Direct Store' in September 2021 to help customers choose from a wide range of health support products.

Shares of Advanced Enzyme Technologies Limited was last trading in BSE at Rs. 372.8 as compared to the previous close of Rs. 366.2. The total number of shares traded during the day was 11499 in over 735 trades.

The stock hit an intraday high of Rs. 375.55 and intraday low of 360. The net turnover during the day was Rs. 4236469.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

Cyient Joins TM Forum to collaborate with global CSPs to drive digital transformation in the Communications industry

BLS International selected as National Business Correspondent for India's largest bank, State Bank of India

Clean Science and Technology Ltd to acquire immovable property for Rs. 32.01 crores

Godrej Industries Ltd to issue NCDs for Rs. 750 crore

HDFC announces festive home loan offer with rates at 6.70%

Fineotex Products now ECO PASSPORT certified by OEKO-TEX®, audit conducted by Hohenstein, Germany

L&T Hydrocarbon Engineering bags significant orders from GAIL, Air Products Middle East Industrial Gases LLC

Hon'ble High Court of Delhi passes an order in favour of EaseMyTrip regarding unsolicited messages

Sterling and Wilson Solar Limited commissions 66 MWp solar energy project in Jordan

RattanIndia Enterprises appoints Mr. Peeyush Kumar as Head for their Drone business

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%

PDS Multinational Fashions Limited appoints Raamann Ahuja as Group Chief Human Resources Officer

Mr. Sumit Kumar Shaw resigns from Websol Energy System Ltd

K P Energy Ltd receives LOI aggregating Rs. 119.73 crores

Gensol Engineering Ltd acquires 51.68% stake in Solarig Gensol Utilities Pvt Ltd

Action Construction Equipment Ltd fixes floor price for QIP as Rs. 254.55

HCL Technologies to Drive Digital Speed, Transformation for MKS Instruments

Choice International Ltd secures IRDAI nod for stake acquisition

SoftSol India Limited to consider loan of $5 mn to subsidiary

Firstsource awarded IIP 'We invest in people' Gold accreditation for the second time in a row

TCS' Quartz™ Named a Leading Crypto Player in Transaction Banking and Payments by Celent

Ind-Ra revises outlook on IVP Limited

Apollo Tricoat Tubes Ltd board allots 3,04,00,000 bonus equity shares

Indian Sucrose Ltd board approves expansion projects

R & B Denims Limited to participate in Cairo Fashion & Tex Fair, 2021

Zydus Healthcare Limited to sell two brands Mifegest and Cytolog

Websol Energy System Ltd announces resignation of CFO - Mr. Sumit Kumar Shaw

Anupam Finserv Ltd fixes Oct 7, 2021 as record date for stock split

Universal Autofoundry Ltd Board to consider Bonus Issue

APL Apollo Tubes Limited allots 12,48,96,000 bonus equity shares

Union Qualtiy Plastics Ltd announces resignation of Mr. Sandeep Kumar Patnaikuni

Wardwizard Innovations and Mobility Ltd approves rights issue of Rs. 49 crores

Ishan Dyes and Chemicals Ltd board approves allotment of 50 lakh warrants

RPP Infra Projects wins new orders worth INR 157.67 Crores

DJ Media Print & Logistics Limited has been empaneled by LIC of India, Divisional Office, Jabalpur

Big Bloc Construction partners with SCG International Corporation Co. Ltd

Tata Power receives 'Letter of Intent' from MAHAGENCO to supply 250 MW power in Maharashtra

Quess Corp's General Staffing division first in India to cross 250,000 associates

Alkem Laboratories Limited to close operations at Beta Block in Baddi facility

Tata Communications offers pay-as-you-go feature on Ethernet network services in India

VST launches 95 DI Ignito - India's first 9 HP Electric start Power Tiller & widest range of Brush Cutters

Equitas Small Finance Bank successfully facilitates over one million vaccinations in collaboration with the state governments of India

L&T Hydrocarbon Engineering wins significant order from Petronet LNG

Adani Green Energy Limited appoints Mr. Romesh Sobti as additional director

Kotak Mahindra Bank Ltd to invest in KFin Technologies Pvt Ltd

Welspun Corp Limited receives multiple orders aggregating to approx. Rs. 1400 crore

Delta Corp Limited to reopen casinos from Sep 20, 2021

Lupin Ltd gets 7 observations from USFDA for Goa facility

DCM Nouvelle Ltd performs Bhoomi Poojan for new plant at Hisar, Haryana

The Sukhjit Starch and Chemicals Ltd board approves warrants issue at Rs. 300


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020